Journal of Clinical Lipidology

Article	Citations
A Single-Dose, Four-way-Crossover Comparative Bioavailability Study of Two Omega-3 Formulations under Fasting and Fed Conditions in Healthy Volunteers	126
Treatment Gap in Prevention of Myocardial Infarction in Rural New York State	124
News from NLA	110
Genetic Testing for Hypertriglyceridemia in Academic Lipid Clinics - Implications for Precision Medicine	94
The Effect of Estrogen and Testosterone on Cholesterol Crystallization	63
Evidence of Direct Hepatic Secretion of Low density Lipoprotein (LDL) in Mice	58
Prevalence of Lipoprotein(a) Measurements in Patients with or at Risk of Cardiovascular Disease	58
†Role of DNA methylation on 15-Lipoxygenase-1 gene expression in Osteoarthritis	55
Lower Activity of Cholesteryl Ester Transfer protein (CETP) and the Risk of Dementia: A Mendelian Randomization Analysis	51
Multi-pathway cholesterol depletion on top of FOLFIRINOX in newly-diagnosed metastatic pancreatic adenocarcinoma	49
Comparison of virtual vs face-to-face medical nutrition therapy in patients with hyperlipidemia	47
Hypercoagulability or coronary artery disease? Polygenic risk score unveils the mystery	45
Effective treatment of statin- and ezetimibe-resistant hyperlipidemia in a patient with active membranous nephrotic syndrome using a PCSK9 inhibitor	43
Assessment of health disparities in secondary ASCVD risk prevention in the elderly population in Greece	40
Healthcare utilization and expenditures among adults with severe hypertriglyceridemia in US clinical practice	40
Disparities in statin use among individuals with and without cancer history across atherosclerotic cardiovascular disease risk categories	39
Lipoprotein(a) concentrations across a global cross-sectional registry	39
Care of youth with lipid disorders: A brief provider survey	34
Genetic mutations and associated phenotypes in familial hypercholesterolemia: A biobank study	34
Hypertriglyceridemia during hospitalization independently associates with mortality in patients with COVID-19	28
From the Editors: New insights into lipid disorders in children and adolescents as well as cardiovascular benefits of pharmacotherapy for weight loss	28
Intima-media thickness in treated and untreated patients with and without familial hypercholesterolemia: A systematic review and meta-analysis	27
Mesenchymal Stromal Cell (MSC) Therapy Improve Nonalcoholic Fatty Liver Disease (NAFLD) in Long Term high Fat Diet (HFD) Induced Obesity (DIO) Mouse	27
Lipoprotein(a) levels in children with homozygous familial hypercholesterolaemia: A cross-sectional study	26
Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes	26

Achievement of low-density lipoprotein cholesterol thresholds in very high-risk atherosclerotic cardiovascular disease	25
Impact of providing genetics-based future cardiovascular risk on LDL-C in patients with familial hypercholesterolemia	24
Managing hypercholesterolemia in adults older than 75 years without a history of atherosclerotic cardiovascular disease: An Expert Clinical Consensus from the National Lipid Association and the Americ	23
Assessment and management of statin-associated muscle symptoms (SAMS): A clinical perspective from the National Lipid Association	22
Socioeconomic Disparities in Dyslipidemia and Associated Complications: From the Latest National Database	22
Niacin (Niacin) and clinical utility, don't be misled by recent niacin (Niacin) metabolite report	22
Association of Lipoprotein(a) with peri-coronary inflammation in persons with and without HIV infection	21
Table of Contents	21
Use of lipid-lowering therapies in patients with CKD and ASCVD: A 1-year update from GOULD	21
Lomitapide in Pediatric Patients with Homozygous Familial Hypercholesterolemia – Analysis of Secondary and Safety Endpoints from the APH-19 Study	20
Characterization of Inclisiran Use in Real World: Prescription Data from Germany	19
From the Editors: Familial hypercholesterolemia: Still underdiagnosed and undertreated	19
⁎ Incidental Coronary Calcium on Non-Gated CT Scans of the Chest: A Stepwise Approach to Addressing Underreporting and Implementing Deep Learning	19
The recognition and appreciation of Familial Hypercholesterolemia among Internal Medicine residents in the United States	19
*Real-World Experience with Inclisiran at a Large Academic Lipid Clinic	19
Unique Case of Management of Severe Hypertriglyceridemia Secondary to Familial Chylomicronemia Syndrome	19
News from the NLA	19
The Healthy Eating Assessment Tool (HEAT): A Aimplified 10-Point Assessment of CHILD-2 Dietary Compliance for Children with Dyslipidemia	17
Acute pancreatitis events among patients with severe hypertriglyceridemia: A retrospective study	17
JCL Roundtable. Obesity, Diabetes, and Liver Disease in Relation to Cardiovascular Risk	17
A variant in the fibronectin (FN1) gene, rs1250229-T, is associated with decreased risk of coronary artery disease in familial hypercholesterolaemia	17
Increased risk of ASCVD in women with PCOS is only partially mediated by incident metabolic comorbidities	17
Elevated lipoprotein(a) levels attenuate LDL-C lowering in acute coronary syndrome patients treated with triple combination lipid-lowering therapy	16
Promoting lipoprotein(a) awareness and testing for risk identification through outreach and teaching (PATRIOT-QI)	16
Cardiovascular and pregnancy outcomes in women with hyperlipidemia with and without hypertension: A real-world evidence study	16
Lipid profile and risk factors for neoatherosclerosis after drug-eluting stent implantation in acute coronary syndrome	15
Dyslipidemia among elderly patients with hyperuricemia and gout: Insights from the National Inpatient Sample	15
The Relationship of Alcohol Consumption and HDL Metabolism in the Multiethnic Dallas Heart Study	15
Triglyceride-rich lipoprotein sphingolipids are altered in primary hypertension: A pilot case-control study	15
Possible explanations for the common clinical familial hypercholesterolemia phenotypes in the Faroe Islands	14
Clinical profile, genetic spectrum and therapy evaluation of 19 Chinese pediatric patients with lipoprotein lipase deficiency	13
Editorial Board	13
Comprehensive assessment of the combined impact of dyslipidemia and inflammation on chronic kidney disease development: A prospective cohort study	13
Management of Atherogenic Dyslipidemia in a Patient with LDL Discordance	12
Fatty acid analysis in serum of patients with elevated lipoprotein(a) and cardiovascular disease undergoing lipoprotein apheresis	12
Disparities Among Gender and Racial Groups in the Achievement of Optimal Lipid Levels in Patients Following Acute Coronary Syndrome	12
†Safety and Efficacy of Bempedoic Acid in Patients with Hypertension	12
Characteristics Associated with Inclisiran Initiation in Outpatient Physician Clinics	12
A Machine-Learning Algorithm using Claims Data to Identify Patients with Homozygous Familial Hypercholesterolemia (HoFH)	12
*An Unsolved Case: FH or Sitosterolemia?	12
Tailored Therapeutic Strategies for the Management of Chylomicronemia Syndrome	11
Genetic Testing Results in a Preventative Cardiology and Inherited Lipid Disorders Clinic	11
Genetic association analyses highlight apolipoprotein B as a determinant of chronic kidney disease in patients with type 2 diabetes	11
Awareness, diagnosis and treatment of heterozygous familial hypercholesterolemia (HeFH) – Results of a US national survey	11
Marked Hypoleptinemia precedes Overt Fat Loss in Immune Checkpoint Inhibitor-induced Acquired Generalized Lipodystrophy	11
The Family Heart Foundation™ Flag, Identify, Network, Deliver—Familial Hypercholesterolemia (FIND-FH™) Program and Collaborative Learning Network (CL	11
Serum mature and furin-cleaved proprotein convertase subtilisin/kexin type 9 levels and their association with cardiovascular events in statin-treated patients with cardiovascular disease	11
Safety and effectiveness of evinacumab in an infant with homozygous familial hypercholesterolemia: A new renaissance for the very young?	11
Screening for Familial Hypercholesterolemia using Epic Secure Chat in Comparison to Epic Letter as Educational Outreach˄	11
†Cardiovascular Trials Over the Last 15 years: Analysis of the Characteristics and Trends of ClinicalTrials.gov Listings from 2008 to 2022	11

Variation in lipoprotein(a) response to potent lipid lowering: The role of apolipoprotein (a) isoform size	11
Carotenoids in familial hypobetalipoproteinemia disorders: Malabsorption in Caco2 cell models and severe deficiency in patients	11
The causal association between lipid-lowering strategies and risk of intracranial aneurysms: A drug-target Mendelian randomization study	10
Association of cumulative low-density lipoprotein cholesterol exposure with vascular function	10
Impact of baseline demographics on lipid profile in patients with ACS: Unmasking hidden drivers	10
Evaluating the underutilization of lipid-lowering therapy in Asian patients – A high-risk population	10
Overcoming the real and imagined barriers to cholesterol screening in pediatrics	10
303 Incremental Benefit of Atherogenic Cholesterol Reduction with Obicetrapib Administered with Moderate-Intensity Statins	10
From the editors: Upcoming treatments for familial chylomicronemia syndrome: Agents that inhibit production of apolipoprotein CIII	10
Treatment Patterns Among Early Inclisiran vs Anti–PCSK9 mAbs Users: A Retrospective Analysis of US Claims Databases	10
Comparative cardiovascular outcomes of triple lipid-lowering therapy versus double therapy in patients with atherosclerotic cardiovascular disease	10
Hypertriglyceridemia induced Pancreatitis is associated with lower Inpatient Morbidity and Mortality compared to Biliary Pancreatitis	9
Accelerated Atherosclerosis in a Patient With Multifactorial Chylomicronemia Syndrome (MCS), Elevated Lp(a), APOE2/4 Genotype and Diabetes Mellitus.	9
Concordance between LDL-C estimated by various formulas and directly measured LDL-C	9
A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice	9
Multidisciplinary Management of Lipoprotein X-Induced Hyperlipidemia Secondary to Drug-Induced Liver Injury	9
Is Tangier disease a rare cause of premature ovarian insufficiency?: A case report	9
Habitual fish oil supplementation, genetic susceptibility of kidney stones and the risk of new-onset kidney stones	9
†Utility of AI-QCPA: Results of the Decisions for Treating Coronary Disease are Changed in Patients Evaluated with Quantified Plaque Analysis	9
Racial Disparities and Modifiable Risk Factors in Black Patients with Familial Hypercholesterolemia	9
Why Are Patients Presenting with STEMI Already on Statin Not Treated with Additional Aggressive Lipid-lowering Agents?	9
Clinical impact of ≥50% reduction of low density lipoprotein cholesterol following lipid lowering therapy on cardiovascular outcomes in patients with acute coronary syndrome	9
Elevated Levels of Lp(a) are Associated with Circulating Levels of PCSK9 and Coronary Atherosclerosis as Detected by Cardiac Computed Tomography Angiography	9
^Polygenic risk score for coronary artery disease predicts atherosclerotic cardiovascular disease in familial hypercholesterolemia	8
Sex differences in the associations of HDL particle concentration and cholesterol efflux capacity with incident coronary artery disease in type 1 diabetes: The RETRO HDLc cohort study	8
ApoB, LDL-C, and non-HDL-C as markers of cardiovascular risk	8
Metabolic syndrome predicts cardiovascular risk and mortality in familial hypercholesterolemia	8
† Safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia	8
Impact of small dense low-density lipoprotein cholesterol and triglyceride-rich lipoproteins on plaque rupture with ST-segment elevation myocardial infarction	8
Functional profiling of LDLR variants: Important evidence for variant classification	8
Time to benefit of intensive lipid lowering therapy in individuals with cardiovascular disease	8
Community pharmacist impact of addressing statin use in patients with diabetes	8
Hourly 4-minute walking breaks from sitting following aerobic exercise reduce postprandial non-HDL cholesterol in healthy young adults: A randomized crossover trial	8
Development and validation of clinical criteria to identify familial chylomicronemia syndrome (FCS) in North America	8
The importance of low-density lipoprotein cholesterol measurement and control as performance measures: A joint Clinical Perspective from the National Lipid Association and the American Society for Pre	8
From the editor: Heroes in a historic time	7
Cardiovascular Mortality and Hospitalization Risk with LDL by CKD Stage in African-American and White US Veterans	7
CAC Scoring as an Index for Subclinical Carotid Atherosclerosis	7
Evaluation of apolipoprotein A5 variants: A cohort of patients with severe hypertriglyceridemia from Turkiye	7
Modifications on lipid profile and high-density lipoprotein function related to treatment with tofacitinib in female patients with rheumatoid arthritis: Impact of previous therapy with biological agen	7
Dysbetalipoproteinamia: Implications for Pre-Conception, Pregnancy and Beyond	7
Early impact of 2018 AHA/ACC/Multisociety Cholesterol Guideline on lipid monitoring after statin initiation	7
Effect of pharmacologic anti-atherosclerotic therapy on carotid intraplaque neovascularization: A systematic review	7
Differences in Clinical outcomes between Non-Obese Hispanic and Asian populations Who have Hyperlipidemia	7
Evaluation of plasma phytosterols in sitosterolemia, their kindreds and hyperlipidemia subjects	7
Assessment of lipid-lowering therapies in high-risk patients with inflammatory joint diseases—Insights from a preventive cardio-rheuma clinic	7
GPIHBP1 autoantibody is an independent risk factor for the recurrence of hypertriglyceridemia-induced acute pancreatitis	7
Fellow Quality Improvement Project: Identification of High Risk CAD Patients and Referral to Newly Established Lipid Clinic, What are the Clinical Implications?	7
Table of Contents	7
Spotlight on Abetalipoproteinemia and Related Hypobetalipoproteinemia Disorders: A Simplified Nomenclature and Clinical Guidelines. †	7
Hyperlipidemia and risk for preclampsia	7
Association between very high HDL-C levels and mortality: A systematic review and meta-analysis	7
Attrition of adipose: Type 2 familial partial lipodystrophy manifesting in severe premature CAD	6
Physician-reported reasons for not intensifying lipid-lowering therapy in patients with recent myocardial infarction	6
From the editor: Lipidology resurgent as the pandemic wanes	6
Differences in Clinical Outcomes between Non-Obese African American and Asian Populations Who have Hyperlipidemia	6
Association between apolipoprotein B and obesity: A cross-sectional analysis of NHANES data	6
Treatment dilemmas faced by women of reproductive age with familial hypercholesterolemia: Case report	6
Lipoprotein(a) screening for cardiac allograft vasculopathy among heart transplant recipients	6
A novel homozygous nonsense variant of LMF1 in pregnancy-induced hypertriglyceridemia with acute pancreatitis	6
Lipoprotein(a): Mirroring Familial Hypercholesterolemia	6
Elevated Serum Small Dense Low Density Lipoprotein Cholesterol and Lipoprotein(a) Levels in Preeclampsia	6
Association of inclisiran initiation on oral antilipemic therapy discontinuation rates	6
Validation of physical examinations of tendon xanthomas and changes in the cutoff values of Achilles tendon thickness on radiography in the clinical criteria of heterozygous familial hypercholesterole	6
Successful lipid-lowering in statin and PCSK9i intolerant patient with mixed hyperlipidemia: A case study of inclisiran as a therapeutic option.	6
Obicetrapib Lowers LDL-C in Patients Taking High Intensity Statins - Results from the ROSE Clinical Trial	6
Equitable Access to Screening and Lipid-Lowering Therapies in a Large Academic Center after Educational Interventions	6
†Food Compass Score is Inversely Related to Inflammatory Markers and Cardiovascular Disease Incidence: Results from the ATTICA Cohort Study (2002-2022)	6
*Sitosterolemia due to a new combination of ABCG8 variants presenting as hemolytic anemia and thrombocytopenia: A case report	5
Remnant cholesterol and cardiovascular and all-cause mortality in Korean adults	5
Sex differences in the presentation, treatment and outcomes of patients with homozygous familial hypercholesterolemia	5
Cardiovascular disease and cholesterol lowering therapy in women and men with molecularly defined heterozygous familial hypercholesterolemia from Brazil	5
Differences in treatment strategies for LDL-cholesterol reduction in a university lipid clinic vs. standard care apart from the use of PCSK9 inhibitors	5
Long-term monitoring of LPL gene replacement therapy: A lexicon of lessons for gene editing or oligonucleotide-based lipid lowering treatments	5
No benefit of vitamin D supplementation on muscle function and health-related quality of life in primary cardiovascular prevention patients with statin-associated muscle symptoms: A randomized control	5
Concerns regarding NMR lipoprotein analyses performed on the Nightingale heath platform – Focus on LDL subclasses	5
What's next for lipoprotein(a)? A National Lipid Association report from an Expert Panel Discussion	5
† Cholesterol treatment trends from 2014 - 2023 in 3 Million US individuals with ASCVD: a retrospective cohort analysis using the Family Heart DatabaseTM	5
Cost-effectiveness of population-wide genomic screening for familial hypercholesterolemia in the United States	5
In memoriam: A tribute to Dr Scott M. Grundy	5

Pancreatitis polygenic risk score is associated with acute pancreatitis in multifactorial chylomicronemia syndrome	5
Remnant cholesterol as a residual risk in atherosclerotic cardiovascular disease patients under statin-based lipid-lowering therapy: A post hoc analysis of the RACING trial	5
Unveiling Compound Heterozygous Familial Hypercholesterolemia	4
Genomic study of maternal lipid traits in early pregnancy concurs with four known adult lipid loci	4
Detailed Family History of Premature Atherosclerotic Cardiovascular Disease to Guide Lipoprotein(a) Testing: The Multi-Ethnic Study of Atherosclerosis	4
Editorial Board	4
Dedicated training in obesity management: A pathway to better physician practice	4
Is hypertriglyceridemia a reliable indicator of cholesterol-depleted Apo B particles?	4
Disparities in access to pharmacotherapies for weight loss and cardiovascular prevention	4
Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2	4
Effect of Dexamethasone on Modulating Lp(a) Levels in COVID-19 Pneumonia	4
Identification of High Cardiovascular Disease Risk Individuals in an Underserved Patient Population Clinic	4
^Sex Disparities in the Treatment and Outcomes of Familial Hypercholesterolemia	4
+Racial Inequities in Coronary Artery Calcium Screening and Follow-up	4
The Food Compass Score is Negatively Related to the Activity of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2) in Healthy Adults.	4
Race/ethnicity and socioeconomic status affect the assessment of lipoprotein(a) levels in clinical practice	4
Severe Hypertriglyceridemia as a Cause of Arterial Thrombosis with Peripheral Embolic Complications.	4
Utilizing gamification to educate internal medicine residents on managing lipids in patients with inflammatory conditions	4
†Obicetrapib Does Not Accumulate in Adipose Tissue: Results from Studies in Man and Non-human Primates	4
Racial Variations in SGLT2 Inhibitor Prescriptions	4
† Effect of plozasiran targeting APOC3 on lipoprotein particle number and size measured by NMR in patients with hypertriglyceridemia	4
Neurodegeneration in familial chylomicronemia syndrome	4
From the editor: A compendium of lipidology progress	4
Association of lipid-lowering drugs with gut microbiota: A Mendelian randomization study	4
Treatment Target Achievement in Patients with Familial Hypercholesterolemia: A Real-World Descriptive Study	4
Moderate Alcohol Consumption and Lipoprotein Subfractions: A Systematic Review of Intervention and Observational Studies	4
In memoriam, Avedis Khachadurian 1926 - Sept 22,2022	4
Corrigendum to “Volanesorsen and triglyceride levels in familial chylomicronemia syndrome: Long-term efficacy and safety data from patients in an open-label extension trial” [Journal of Clinical Lipid	4
Pegylated-Asparaginase Induced Severe Hypertriglyceridemia in an Adult with Acute B-cell Lymphoblastic Leukemia	4
Comprehensive analysis of Chinese patients with non-LPL familial chylomicronemia syndrome: Genetic variants, dietary interventions, and clinical insights	4
Composition and distribution of lipoproteins after evolocumab in familial dysbetalipoproteinemia: A randomized controlled trial	4
Severe Medication Induced Dyslipidemia in an Adult with Breast Cancer	4
Premature coronary artery disease in the absence of traditional risk factors - a hidden dilemma	4
Addressing residual risk beyond statin therapy: New targets in the management of dyslipidaemias–A report from the European Society of Cardiology Cardiovascular Round Table	4
†Plozasiran (ARO-APOC3), an Investigational RNAi, Demonstrates Deep and Durable TG Reductions in Patients With SHTG, SHASTA-2 Final Results	4
Discontinuation of lipid-modifying agents and failure to achieve target LDL cholesterol levels across cardiovascular risk groups	4
*A Novel ABCG8 Variant and Apo(A) Short Isoform Associated with Premature Atherosclerosis and Familial Hypercholesterolemia Phenocopy.	4
The analysis of the breakpoint of large rearrangements of LDLR gene in a Taiwanese cohort of patients with familial hypercholesterolemia	4
†Efficacy and Safety of Bempedoic Acid in Patients with Metabolic Syndrome	4
Negative LDL-C levels with Detectable Apolipoprotein B: Surrogate Markers of Atherosclerotic Disease and Cardiac Event Risk	4
† Higher Cardiovascular Event Rates for High-Risk Americans Who Did Not Meet 2018 Multidisciplinary Guideline on the Management of Blood Cholesterol Thresholds	4
Oral semaglutide and reduction in major adverse cardiovascular events	4
Association of lipoprotein(a) with peripheral artery disease and outcomes: A propensity-matched retrospective analysis	3
Effect of hormone replacement therapy on in-hospital outcomes of ischemic stroke in older women with dyslipidemia: A large-scale nationwide analysis	3
Lipoprotein(a), metabolic profile and new-onset type 2 diabetes in patients with familial combined hyperlipidemia: A 9 year follow-up study	3
Adherence to lipid monitoring and its impact on treatment intensification of LDL-C lowering therapies at an urban academic medical center	3
Racial disparities in LDL-C control, ASCVD risk reclassification by statin use, coronary artery calcium scores, and the Pooled Cohort Equation	3
A case of lipoprotein glomerulopathy due to the pathogenic APOE Las Vegas variant c.509C > A: p. (Ala170Asp)	3
†Obicetrapib Treatment Increases Pre-Beta1 HDL and Lipophilic Antioxidants in the Ocean and Rose2 Studies	3
Acknowledgement of Referees	3
One size doesn't fit all: A dose-dependent twist in PCSK9 monoclonal antibody therapy	3
Corrigendum to Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association [Journal of Clinical Lipidology Volume 13, Issue	3
Healthcare costs among acute pancreatitis patients with severe hypertriglyceridemia	3
A Single-Dose, Randomized, Open-Label, Two-Period Crossover Bioequivalence Study in Healthy Adults Comparing Two Subcutaneous Formulations of Olezarsen: (Vial and Autoinjector) at Two Dose Levels	3
CME Activity Highlights the Improvement in Clinician's Knowledge and Competence about Treatment Choices for LDL-C Lowering Post-MI	3
Timing of PCSK9i Initiation and Its Relationship with Clinical Outcomes in US Patients with Prior Cardiovascular Events: A Claims Database Analysis	3
Impact of conducting a genetic study on the management of familial hypercholesterolemia	3
Improving cholesterol management in high-risk primary prevention patients: An evidence-based case series	3
Case Report - Lysosomal Acid Lipase Deficiency - A Rare Cardiometabolic Disease and a NAFLD Mimic	3
Statin therapy for primary prevention in women: What is the role for coronary artery calcium?	3
Evaluation of Lp(a) for cardiovascular disease risk prediction in the veteran's health administration	3
Attitudes and barriers to lipoprotein(a) testing: A survey of providers at the University of Pennsylvania Health System	3
Improving adherence with lipid-lowering agents	3
Predicting resilience in heterozygous familial hypercholesterolaemia: A cohort study of octogenarian patients	3
Diagnosis and Management of Familial Dysbetalipoproteinemia in a Patient with Apo E2/E2 Genotype	3
Lipids management in patients with diabetes mellitus: Experience from a cohort study in Greece.	3
Successful pregnancy outcome in a woman with cholesteryl ester storage disease treated with enzyme replacement therapy	3
Eicosapentaenoic Acid Reverses Endothelial Dysfunction following Exposure to the Cytokine IL-6 in Contrast to Docosahexaenoic and Arachidonic Acids	3
Heterozygous pathogenic PPARG variants in patients with severe hypertriglyceridemia	3
JCL Roundtable: Dietary recommendations and intermittent fasting and time-restricted eating	2
Outcomes of hyperglycemic emergencies among African Americans compared to Caucasians: A large-scale nationwide analysis	2
Intubation rates and risk factors in SLE patients with protein-calorie malnutrition	2
The Paradox of Ketogenic diet and Dyslipidemia	2
Effects of Music Therapy on Psychological Constructs and Atherogenic Lipoproteins in Patients with Severe Hypercholesterolemia	2
Small interfering ribonucleic acid for cholesterol lowering – Inclisiran	2
Health-related quality of life in homozygous familial hypercholesterolemia: A systematic review and meta-analysis	2
LpX and LpZ associated hypercholesterolemia in a patient with primary sclerosing cholangitis – A case report	2
News from NLA	2
Impact of PCSK9 monoclonal antibody inhibitors on Lp(a) reduction in African Americans with elevated Lp(a)	2
Impact of value-based comprehensive medication management on statin prescribing in patients with type 2 diabetes mellitus	2
*Pericardial and Pleural Effusions after Evolocumab in a Patient with Severe Familial Hypercholesterolemia	2
Cardiometabolic risk factors in young adults with acute myocardial infarction.	2
Improved arterial inflammation with high dose omega-3 fatty acids in patients with elevated lipoprotein(a): Selective effect of eicosapentaenoic acid?	2
Unfavorably altered lipid profile in women with primary ovarian insufficiency	2
Adherence to statin treatment in patients with familial hypercholesterolemia: A dynamic prediction model	2
Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association	2
From the Editors: New concepts in obesity and cardiovascular disease	2
High burden of disease in patients with homozygous familial hypercholesterolemia despite recent advances in therapies and updated guidelines: A real-world study	2
Trends and experience with lipoprotein(a) testing in a large academic medical center	2
Multiple Myeloma and Hyperlipidemia - coincidence or related?	2
From the editor: Coyotes on the lawn	2
The effect of adjusting LDL-cholesterol for Lp(a)-cholesterol on the diagnosis of familial hypercholesterolaemia	2
Prevalence, pattern, and correlates of dyslipidemia in Bangladeshi individuals	2
Mediation effect of metabolic factors and inflammation on the association of serum uric acid with serum proprotein convertase subtilisin/kexin type 9 levels	2
Global disparities in access to lipid-lowering therapies for patients with homozygous familial hypercholesterolemia – A physician survey	2